Hot Sale Supply Valganciclovir Hydrochloride Powder CAS 175865-59-5 with Safe Delivery

Min.Order / FOB Price:Get Latest Price

1 Kilogram	FOB Price: USD 50.0000

1 Kilogram

FOB Price: USD 50.0000

Min.Order :1 Kilogram
Purity: 99%
Payment Terms : T/T,Other

Keywords

Valganciclovir Hydrochloride 175865-59-5 Pharmaceutical Intermediates

Quick Details

Appearance:White powder
Application:Valganciclovir hydrochloride?is used for preventing and treating CMV infection secondary to organ transplant recipients. This drug is a prodrug of ganciclovir, and it is an active valine ester of ganc
PackAge:bag
ProductionCapacity:10|Kilogram|Day
Storage:2-8℃
Transportation:air

Superiority:

purity min99%

Large volume discount

Our advantage:
We have PEPTIDES and SARMS WAREHOUSE IN USA and Euro, you can receive order with 3 days without any customs problems.
We offer drop ship to your end clients in worldwide.

Why Choose us:
1). We have our own GMP lab .
2). Warehouses in USA and Euro to support your urgent need.
3). We can customize Peptides and Test Report HPLC and MS are available.
4). / Bank Transfer / Credit Card / Bitcoin / T/T in Advance / LC @ SIGHT / Paypal for your option.

Details:

Product description

Product name	Valganciclovir hydrochloride
CAS No.	175865-59-5
Molecular Formula	C14H23ClN6O5
Molecular weight	390.82
Grade Standard	Medicine Grade
COA	Avaliable

Product introduction

Valganciclovir hydrochloride, a prodrug of the antiviral ganciclovir, was launched in the US for the oral treatment of cytemegalovirus (CMV) retinitis, a sight-threatening complication in patients with AIDS. Valganciclovir is well absorbed and rapidly hydrolyzed to ganciclovir by intracellular esterases in the intestinal mucosal cells and by hepatic esterases. Unlike ganciclovir, valganciclovir was demonstrated to be actively transported by the intestinal peptide transporter PEPT1 in Caco-2 cells. As a consequence, its absolute bioavailability in human was 10-fold higher compared to ganciclovir (6%). In clinical trials, it was shown that a twice-daily 900 mg dose of valganciclovir resulted in similar systemic ganciclovir exposure to 5 mg/kg twice-daily intravenous injection of ganciclovir. Valganciclovir concentrations could not be quantified in most patients within three to four hours. In a randomized non-blind phase III clinical trial, oral valganciclovir (900 mg twice daily for three weeks then 900 mg once daily for one week) was as effective as intravenous ganciclovir (5 mg/kg twice daily for three weeks then 5 mg/kg once daily). Oral treatment with valganciclovir avoided catheter-related infection that sometimes occurred with intravenous ganciclovir.